Scholarlink

Background <p>Apert syndrome is a syndromic craniosynostosis primarily caused by pathogenic mutations in the fibroblast growth factor receptor 2 (<i>FGFR2</i>) gene. Current prenatal diagnosis of Apert syndrome predominantly relies on ultrasound imaging in the third trimester (28 weeks of gestation to delivery), which is not conducive to early clinical decision-making.</p> Case presentation <p>In this case, prenatal ultrasound at the 20 weeks of gestation revealed craniosynostosis, oligohydramnios, and syndactyly of hands and feet in the fetus. Whole-exome sequencing (WES) followed by Sanger sequencing was performed on the affected fetus and its parents. A <i>de novo</i> pathogenic mutation in the <i>FGFR2</i> gene was identified. Based on the fetal ultrasound findings and genetic test results, Apert syndrome was diagnosed as early as the 20 weeks of gestation (second trimester).</p> Conclusions <p>The combination of prenatal ultrasound and WES enables the diagnosis of Apert syndrome in the second trimester, providing valuable support for early prenatal counseling and pregnancy management.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Prenatal diagnosis of Apert syndrome caused by a de novo FGFR2 mutation in the second trimester: a case report

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年5月26日

查看全文
  • Xiaoying Chen,
  • Pengzhen Jin,
  • Min Chen,
  • Juan Zuo,
  • Jie Liu,
  • Jin Zhu,
  • Miaochun Lin,
  • Zhaohui Li,
  • Minyue Dong

摘要

Background

Apert syndrome is a syndromic craniosynostosis primarily caused by pathogenic mutations in the fibroblast growth factor receptor 2 (FGFR2) gene. Current prenatal diagnosis of Apert syndrome predominantly relies on ultrasound imaging in the third trimester (28 weeks of gestation to delivery), which is not conducive to early clinical decision-making.

Case presentation

In this case, prenatal ultrasound at the 20 weeks of gestation revealed craniosynostosis, oligohydramnios, and syndactyly of hands and feet in the fetus. Whole-exome sequencing (WES) followed by Sanger sequencing was performed on the affected fetus and its parents. A de novo pathogenic mutation in the FGFR2 gene was identified. Based on the fetal ultrasound findings and genetic test results, Apert syndrome was diagnosed as early as the 20 weeks of gestation (second trimester).

Conclusions

The combination of prenatal ultrasound and WES enables the diagnosis of Apert syndrome in the second trimester, providing valuable support for early prenatal counseling and pregnancy management.